PGF 2 in urine, before and up to 72 h after the bronchial allergen challenge, by means of enzyme-linked immunoassay (ELISA/EIA) or ImmunoCAP. Results: DYAR was accompanied by a significant increase in the plasma concentrations of LTB 4 (p ! 0.05) and myeloperoxidase (p ! 0.05) at 24, 36 and 48 h after the challenge, whereas the plasma/serum or urine concentrations of the other factors did not demonstrate any significant changes (p 1 0.05). Conclusions: These results would indicate an active and prominent involvement of neutrophils, in addition to the previously demonstrated role of the Th1 lymphocytes, in the clinical DYAR.
1999 and 2000 and developing DYAR ( fig. 1 ) during the routine bronchial provocation tests (BPTs) with inhalant allergens [7] , volunteered to participate in this study.
These patients, 20-45 years of age, showed reversible bronchial constriction alternating with symptom-free periods without any restrictive changes of their lung function. They did not suffer from respiratory infections. They had not been treated with oral corticosteroids or immunotherapy. They were examined using a routine diagnostic procedure, serving also as inclusion-exclusion criteria ( tables 1 , 2 ) [7] , consisting of (1) a general part: disease history, physical examination, basic laboratory tests, X-ray of the chest and sinuses, lung function, blood gas determination, bacteriological examination of the sputum; (2) an allergologic part: skin tests, bronchial histamine threshold [44] , blood leukocyte differential count, determination of the serum immunoglobulins; (3) control challenge with phosphate-buffered saline (PBS; n = 25) followed by bronchial challenges with allergens (BPTs; n = 58). The allergens for BPTs were chosen with respect to disease history and skin tests ( table 3 ) . The initial BPTs have always been performed with allergenic extracts diluted 1: 10 and if they were negative, then BPTs with undiluted extracts (our standard) followed ( table 3 ) .
In these 25 patients demonstrating DYAR during the routine procedure (amplitude 44 8 8%, mean 8 SD) ( fig. 1 ), the BPTs with the same allergens ( table 3 ) and PBS controls were repeated 2-6 weeks later. The repeated DYARs and PBS challenges ( fig. 1 ) were supplemented with the recording of various in vivo and in vitro response-related diagnostic parameters and particular factors in the blood serum/plasma before and up to 72 h after the allergen challenge ( table 4 ) . The local ethical committee approved this study, and an informed consent was obtained from all study participants. /l; blood leukocyte count 4.0-10.0 ! 10 9 /l; blood eosinophil count <300 ! 10 6 /l; blood thrombocyte count 150-400 ! 10 9 /l; blood differential count: 0.0-0.15 ! 10 9 /l (basophils), 0.0-0.50 !10 9 /l (eosinophils), 2.0-7.2 ! 10 9 /l (neutrophils), 0.15-0.9 ! 10 9 /l (monocytes), 1.0-4.0 ! 10 9 /l (lymphocytes); erythrocyte sedimentation rate <20 mm/1 h; histamine ≤1.5 ng/ml, percentage of 'completes' (total potential content of histamine in the blood, mostly in basophils). 1 Concentrations of particular factors in urine are related to urine creatinine (C). 
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Control Subjects
Three groups of control subjects volunteered to participate in this study: 36 asthmatics demonstrating an isolated IAR/EAR (amplitude 32 8 11%), 31 asthmatics developing an isolated LAR (amplitude 35 8 9%) and 38 healthy subjects ( tables 1 , 2 ).
Allergens
Dialyzed and lyophilized allergen extracts (Allergopharma, Reinbek, Germany) diluted in PBS were used in concentrations of 100-500 biologic units (BU)/ml for skin tests and 1,000-3,000 BU/ml for BPTs ( table 3 ). The recommended concentrations by the manufacturer were 500 BU/ml for skin tests and up to 5,000 BU/ml for bronchoprovocation.
Skin Tests
Scratch tests with allergenic extracts in a concentration of 500 BU/ml were carried out and evaluated after 20 min. If negative, then intradermal tests were performed in concentrations of 100 BU/ml, and then 500 BU/ml, and evaluated 20 min, 6, 12, 24, 36, 48, 72 and 96 h after the intracutaneous injection. A skin wheal reaction ( 1 7.0 mm in diameter) appearing 20 min after the injection was considered to be a positive immediate skin response, skin infiltration occurring between 6 and 12 h to be a late skin response, and skin induration recorded later than 48 h was designated a delayed skin response [4] [5] [6] [7] .
Bronchial Provocation Tests (BPT)
The BPTs were performed by means of spirometry (Spirograph D-75, Lode, Groningen, The Netherlands) recording the forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV 1 ) values. The FEV 1 values and FEV 1 /FVC ratio were considered to be indicative parameters for bronchial obstruction. The aerosolized allergen extracts and PBS were administered to the patients by means of the Wiesbadener Doppel Inhalator at an airflow of 10 l/min. The nebulizer output was 0.12-0.14 ml/min and the aerosol particles had a median mass diameter of 2.8-3.6 m.
The BPTs [4] [5] [6] [7] 44] were performed according to the following schedule: (1) baseline values recorded at 0, 5 and 10 min; (2) PBS control values recorded at 0, 5 and 10 min after a 10-min PBS inhalation; (3) inhalation of the allergen aerosol for 2 ! 5 min, with inserted FEV 1 and FVC measurement, followed by recording of the spirometric values at 0, 5, 10, 20, 30, 45, 60, 90 and 120 min and every hour up to the 12th hour and every second hour during the 22nd and 38th and the 46th and 56th hour interval [6] . A 5-day interval was always inserted between the end of the preceding test and the beginning of the following test to prevent carryover effects and to allow patient recovery.
All BPTs were performed in a period without manifest bronchial complaints, outside the allergen-relevant season and during hospitalization under standard conditions. Inhaled glucocorticosteroids (n = 15) and long-acting ␤ 2 -sympathomimetics (n = 2) were withdrawn 4 weeks, cromolyn (n = 1), nedocromil sodium (n = 5), anti-leukotrienes (n = 1) and xanthine derivates (n = 1) 2 weeks, while short-acting ␤ 2 -sympathomimetics and histamine H 1 receptor antagonists 48 h before each BPT. The FEV 1 decrease of 6 50%, with respect to the predicted values, was treated with inhalation of a single dose of 200-400 g salbutamol.
Other Diagnostic Parameters
In vivo and in vitro diagnostic parameters were recorded either singly ( tables 1 , 2 ) or repeatedly during the repeated DYARs and PBS controls ( table 4 ). Th1/Th2 ratio (%) values in peripheral blood were determined by means of flow cytometry, and the intracellular cytokines in the peripheral blood mononuclear cells, interferon-␥ and interleukin-4 were estimated by means of immunoassay ELISA kits, as described in detail previously [7] . Histamine serum concentrations, so-called 'blanks', were measured by Siraganian's fluorometric method [7, 45] .
Supplementary Immunologic Parameters Blood
The samples of venous blood were obtained before and then at 1, 12, 24, 36, 48, 56 and 72 h after the allergen challenge. Venous blood samples (5 ml) were collected into separator tubes (SMonivette, Sarstedt, Germany), kept at room temperature for 1 h and then centrifuged at 3,000 ! g for 10 min at 4 ° C. The serum supernatants were removed, stored at 2-8 ° C and processed with- in 1 h. Other venous blood portions were collected in vacutainers containing EDTA, kept for 1 h at room temperature and then centrifuged at 2,500 ! g for 10 min at 4 ° C. The plasma supernatants were removed and processed within 1 h. The resting aliquots were stored at -70 ° C.
The serum/plasma levels of appropriate factors were measured by using commercially available kits, following manufacturers' recommendations. Tryptase, eosinophil cationic protein (ECP), eosinophilic peroxidase (EPO) and eosinophil-derived neurotoxin (EDN) were estimated in the serum, whereas all other factors were determined in the plasma. All measurements were performed in duplicate by a double-blind schedule. The intra-assay as well as the inter-assay coefficients of variation for all the assay kits employed were ! 10%. (1) Urine samples were centrifuged at 1,350 ! g for 10 min at 4 ° C, aliquoted (20-30 ml each), transferred to plastic tubes, stored at 4 ° C and analyzed within 1 h. The concentrations of particular factors were measured by using commercially available kits, following the manufacturers' recommendations and related to urine creatinine determined by the alkaline picrate method (Grainer Diagnostics AG, Langenthal, Switzerland). All measurements were performed in duplicate by a double-blind schedule. The intra-assay as well as the inter-assay coefficients of variations for all the assay kits employed were ! 10%. (1) LTE 4 -EIA kit (Cayman Chemical). DL for LTE 4 was 25 pg/ml. (2) 9 ␣ ,11 ␤ -PGF 2 -EIA kit (Cayman Chemical). DL for 9 ␣ ,11 ␤ -PGF 2 was 5.5 pg/ml. (3) TXB 2 -EIA kit (Cayman Chemical). DL for TXB 2 was 11 pg/ml. (4) EPX/EDN -ELISA kit (MBL International). DL for EPX/EDN was 0.62 ng/ml.
Statistical Analysis
The BPTs were statistically evaluated by means of fitting polynomials to the mean curves over time: 8 time points within 120 min and 20 time points up to 56 h after the allergen challenge. The hypotheses were tested by generalized multivariate analysis of variance (MANOVA) [46] . The post-challenge values of particular factors recorded at each of the time points during DYAR as well as the PBS control test in individual patients were compared with their pre-challenge values and evaluated by the Wilcoxon matched-pair signed rank test. The mean post-challenge values measured at each of the time points during DYAR were 
Results
DYAR recorded in 25 asthma patients began within 26-32 h, reached a maximum within 32-48 h and resolved within 56 h ( fig. 1 ) . DYAR was statistically highly significant as compared with the PBS control challenge (p ! 0.001). Repeated DYAR ( fig. 1 ) was also statistically highly significant both in comparing the post-challenge with the pre-challenge FEV 1 values (p ! 0.01) and as compared with the PBS control challenge (p ! 0.001).
No significant differences were found between the initial and the repeated DYARs (p 1 0.1).
The initial as well as the repeated DYAR were associated with dyspnea, wheezing, increased blood leukocyte, neutrophil and lymphocyte counts, non-increased eosinophil count, significant changes in the Th1/Th2 cell ratio in peripheral blood in favor of Th1 cells (p ! 0.01) and a significant increase in the intracellular concentration of Dat a are means 8 SD. 0 = Normal (negative, no changes); -= not determined; & = doubtful value. Statistical significance: a p ≤ 0.05; b p < 0.05; c p < 0.01. Normal values: total IgE <500 IU/ml; specific IgE < 0.70 U/ml; total IgG <15.0 g/l; blood leukocyte count 4.0-10 ! 10 9 /l; blood eosinophil count <300 ! 10 6 /l; blood thrombocyte count 150-400 ! 10 9 /l; blood neutrophil count 2.0-7.2 ! 10 9 /l; blood differential count <0.2 ! 10 9 /l (basophils), . No significant differences were found between the duplicated measurements of these factors in the blood (p 1 0.1). No significant concentration changes of these factors were measured in the peripheral blood during the PBS controls (p 1 0.05; table 5 ).
The concentrations of LTE 4 , 9 ␣ ,11 ␤ -PGF 2 , TXB 2 and EDN/EPX recorded in the urine did not demonstrate any significant changes during DYAR or PBS control challenge ( table 6 ) . No significant differences were found between the values of these factors recorded in the duplicates of urine (p 1 0.05).
No statistically significant differences in the pre-challenge concentrations of these factors were recorded in the peripheral blood of the control patients developing IAR and LAR, or in healthy subjects as compared with those measured in the DYAR patients (p 1 0.05, 1 0.1 and 1 0.01, respectively) ( table 1 ).
Discussion
DYAR differs from IAR/EAR and LAR in its clinical course and features, association with various in vivo and in vitro diagnostic parameters, immunologic features and hypersensitivity types underlying these asthmatic responses [4-8, 10, 15, 16, 20-25, 42] .
Each of the hypersensitivity mechanisms is characterized by typical involvement of particular cell types, releasing a complex of mediators, chemotactic factors, eicosanoids, cytokines, chemokines, immunoglobulins enzymes and expressing typical adhesion molecules and receptors (CD molecules). The individual cell types, activated by various intercellular signal mechanisms, follow specific traffic patterns on various levels in the blood and bronchial tissue (epithelium, mucosal and submucosal layers, smooth muscles and secretory glands), leading to a variety of inflammatory processes, bronchoconstriction, increased sputum production and airway remodeling [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] .
Additionally, a number of other factors, such as particular clotting system, metabolic system, hormones and Con centrations of particular factors in urine are related to the urine creatinine concentration (C).
genetic factors, can directly or indirectly contribute to the individual hypersensitivity mechanisms underlying the particular types of asthmatic response [1] [2] [3] . Despite our extensive knowledge, the detailed extent of all immunologic and metabolic mechanisms involved in the particular types of asthmatic response to allergen challenge is not yet fully clarified [1-5, 7, 9-13, 17, 19, 26, 27, 48, 59, 60] .
Most of the clinical and research data have been gathered from asthma patients without further differentiation of the particular types of asthmatic response by means of BPTs [18, 19, 26, 29, 31, 33-39, 41, 43, 49-51, 58, 61-67] . Such an approach resulted in the collection of data which cannot be properly related to specific and well-defined types of hypersensitivity and the underlying immunologic processes. The BPT with allergen is the only method demonstrating the existence and participation of a certain type of asthmatic response in the individual patient to which the other in vivo and in vitro diagnostic parameters and immunologic aspects can be related [4-8, 10, 14-16, 19-25, 30, 32, 52-57] .
In most of the in vivo studies, either the single estimation of these factors has been performed in the (induced) sputum [19, 26, 47, 51, [61] [62] [63] [64] [65] [66] [67] , bronchoalveolar lavage (BAL) fluid [18, 50] , blood [14, 35, 40-41, 51, 59, 65, 67] , lung biopsy [26, 43] , urine [35] or exhaled breath condensate [58] , or their concentrations were measured repeatedly in BAL fluid [8, 14, 15, 20, 21, 42, 53, 54] , induced sputum [22, 28, 31, 55] , blood [7, 15, 16, 30, 39, 52] , exhaled breath condensate [56] , urine [23, 24, 30, 32, 57] or lung biopsy [15] after a segmental/endobronchial provocation with allergen. However, the changes of these factors in sputum, BAL fluid, urine or exhaled breath condensate were usually measured within a relatively short period of time, usually 1-2 h [8, 53, 54] , and exceptionally up to 12 h [16, 20, 23] or 24 h [15, 21, 22, 52] after the allergen provocation.
Relatively few studies deal with the determination of these factors in BAL fluid [8, 21, 42] , induced sputum [22, 28, 31, 55] , blood [16, 25, 52, 68] , urine [23, 24, 32, 57] or exhaled breath condensate [56] after a BPT performed by inhalation of allergen. In some of these studies, the recorded factor changes are related to the particular types of the asthmatic response, such as an IAR [4, 16, 23-25, 28, 42, 53, 57] or LAR [5, 15, 16, 21-25, 31, 55, 56] .
In most of the in vitro studies, the changes of these factors were measured after a non-specific stimulation [14, 18, 33, 53, 54] or sporadically after an allergen-specific stimulation [39] of the particular cell types, e.g., eosinophils, basophils, neutrophils and alveolar macrophages, isolated from the BAL fluid, induced sputum or peripheral blood [14, 34, 36, 39] . The patients included in these studies mostly demonstrated the classical type of bronchial asthma attributed to the immediate hypersensitivity upon involvement of immunoglobulin E (IgE) antibody, mast cells/basophils, eosinophils and Th2 lymphocytes [1, 2] .
However, the growing importance of LAR [1-3, 5, 8, 10, 15, 16, 20-25, 35, 42, 52] , together with findings of absence of IgE antibody and/or eosinophilia, in some asthmatic patients, would indicate additional involvement of the so-called 'non-immediate' (non-IgE, IgE-independent) mechanisms in bronchial asthma [59, 60] . The later reported existence of the various phenotypes of bronchial asthma, such as the eosinophilic, non-eosinophilic, neutrophilic and paucigranulocytic type [9, 11-13, 19, 26-28, 50, 62-67] , creates a necessity for more and focused research of the role of non-immediate hypersensitivity mechanisms in the clinical bronchial asthma.
The target of this clinical study was to investigate the possible participation of the mast cells, basophils, eosinophils and neutrophils, in addition to the already documented involvement of Th1 cells, in the mechanism(s) underlying DYAR [7, 68] .
The role of LTs, PGs and other products of activated target cells such as eosinophils, neutrophils, mast cells, basophils, lymphocytes, alveolar macrophages and bronchial epithelial cells in bronchial asthma has already been investigated from various points of view [8, 14-26, 28-43, 47, 49-59] .
Our findings of an increased count of neutrophils [7, 68] and increased secretion of their products, such as LTB 4 and MPO ( table 5 ), in the peripheral blood during DYAR is partly consistent with the other investigators' reports of the existence of an asthma phenotype associated with increased neutrophil, but not eosinophil, count in peripheral blood [9, 11, 19, 30, 33, 65, 67] , sputum or BAL fluid [8, 12, 19-21, 26-28, 50, 62-67] . Therefore, DYAR would represent a new phenotype of bronchial asthma, where the neutrophils and Th1 cells may play a pivotal role, besides the already reported other asthma phenotypes [1-3, 9, 11-17, 19, 26, 31, 38, 39, 47, 50, 59, 61-67] .
In most patients with bronchial asthma, especially in those in whom the immediate hypersensitivity may play a predominant role, an increased count of circulating eosinophils and sometimes also basophils, increased concentrations of allergen-specific IgE, histamine, LTC 4 , ECP, EPO, EDN and sometimes tryptase and PGs in blood have been reported [14-16, 20-22, 29, 31, 41, 51-55, 61] .
These results are consistent with findings of increased concentrations of various factors in the BAL fluid and induced sputum of patients suffering from bronchial asthma due probably to the immediate hypersensitivity, such as histamine [8, 20, 42, 47, 53] , tryptase [28] , LTC 4 [8, 47, 53] , LTB 4 [21, 36] , LTE 4 [42] , LTD 4 [47] , PGD 2 [8, 42, 53, 54] , PGF 2 ␣ [20] , ECP [14, 18, 28, 31, 47, 51] , TXB 2 [8, 20, 42, 53] , or LXA 4 [40] . Also, increased concentrations of LTE 4 [30] and PGF 2 ␣ [30] were found in the urine of asthmatics. The comparable changes, mostly an increase in concentration of these factors, were observed in the BAL fluid or induced sputum after the BPT [16, 21, 22, 28, 31, 55] or the segmental provocation with allergen [15, 42, 53, 54] in asthmatics who have developed either IAR [31, 51, 55] or LAR [8, 15, 20-22, 28, 31, 53-55] . The increased concentrations of MPO and LTB 4 were found in blood [29, 35, 41] , sputum and BAL [19, 37, 50] or in exhaled breath condensate [37, 49] of asthmatics.
However, significant changes in the concentrations of MPO or LTB 4 in the blood of the patients developing either IAR or LAR to allergen challenge were not found by us in the available literature.
In contrast, significantly increased concentrations of LTB 4 and MPO have been measured in the peripheral blood during DYAR ( table 5 ) . No significant changes in blood concentrations of LTC 4 , LTE 4 , PGD 2 , PGE 2 , PGF 2 ␣ , TXB 2 , LXA 4 , ECP, EDN, EPO or tryptase or in urine concentrations of LTE4, TXB 2 , 9 ␣ ,11 ␤ -PGF 2 or EDN/EPX were recorded during DYAR ( tables 5 , 6 ).
However, some of the aspects concerning the possible mechanism(s) involved in DYAR may probably be detected and clarified by serial determination of the abovestudied factors in repeated (induced) sputum, BAL and/ or bronchial biopsies. Unfortunately, no reliable data concerning the appearance and changes of eicosanoids, eosinophil and neutrophil constituents in the (induced) sputum, BAL or lung biopsy during DYAR were available due to technical as well as ethical reasons. This fact may be regarded as a certain deficit of this study and a limitation of the above-presented results.
These findings would support evidence for an involvement of neutrophils, and possibly also monocytes and macrophages, in the immunologic mechanism(s) underlying DYAR. Together with evidence of an active role of Th1 lymphocytes in DYAR [7] , these results suggest the possible involvement of delayed (cell-mediated) hypersensitivity mechanism(s) in DYAR. Nevertheless, further concurrent clinical and immunologic studies will be needed to clarify the immunologic mechanisms underlying this clinical phenomenon.
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